GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.

Education

Biotechnology

GentiBio

Tom Crevier

Tom Wickham

Alexa Perdikis

Jaii Fredregill

Rachel Yost

Marko Repic

Adan Jaramillo

Chuck Silberstein

Heidi Chandler

Margaret Readio

Alberto del Rio Espinola

Jennifer Hu

John Wesner

Nishat Shaikh

Christopher L. Moore

Tiffany Chen

Nicole R. Reed

Madison Milaszewski

Tim Guo (Tingxi)

Pramod Kumar Rompikuntal

Abby Meiners

Scientific Research and Development

Directors

Scientific Advisory Team

Leadership Team

Operations Team

Teams at GentiBio

Scientific Research and Development

Directors

Scientific Advisory Team

Leadership Team

Operations Team